SubHero Banner
Text

Brukinsa® (zanubrutinib) – New orphan indication

September 1, 2021 - BeiGene announced the FDA approval of Brukinsa (zanubrutinib), for the treatment of adult patients with Waldenström’s macroglobulinemia (WM).

Download PDF